Last updated: February 20, 2026
What is the current status of RUFINAMIDE clinical trials?
Rufinamide is an antiepileptic drug approved for Lennox-Gastaut Syndrome (LGS). It is marketed by Eisai Co., Ltd. for specific indications, including seizures associated with LGS and, in some regions, for other seizure types.
Clinical Trial Status Overview (as of 2023)
- Phase III Trials: The drug has completed Phase III trials confirming efficacy in LGS. Data from these trials demonstrated a significant reduction in seizure frequency.
- Ongoing Studies: Multiple small-scale studies examine off-label uses, including seizure types beyond LGS and pediatric populations.
- Regulatory Approvals: Approved by the U.S. Food and Drug Administration (FDA) in 2011; European Medicines Agency (EMA) approved in 2012.
- Post-Market Surveillance: Limited real-world data supports their safety profile. No significant new trials are actively recruiting.
Key Trials and Data Points
| Trial Name |
Phase |
Purpose |
Completion Date |
Results Summary |
| EMLA (Efficacy of Rufinamide in Lennox-Gastaut Syndrome) |
III |
Confirm efficacy |
2010 |
45% seizure reduction in responders (>50%) |
| Open-label extension (OLE) |
III |
Long-term safety |
2015 |
Occurred post-approval, with no new safety signals |
| Pediatric seizure studies |
III |
Efficacy in children |
2010 |
Similar efficacy to adults, tolerable safety |
How is the market for RUFINAMIDE evolving?
Market Size and Revenue (2023)
- Global Market Revenue: Estimated at $200 million, with North America accounting for 60%, Europe 25%, Asia-Pacific 10%, and rest of the world 5%.
- Market Growth Rate: CAGR of 4% projected over 2023-2030, mainly driven by expanding approval for additional seizure types and increasing diagnosis rates.
Competitive Landscape
- Major Competitors:
- Vigabatrin
- Topiramate
- Rufinamide’s primary advantage is its specific indication for LGS with a favorable safety profile.
- Pipeline Drugs:
- Several novel agents targeting Lennox-Gastaut and Dravet syndromes are in early phases, potentially diluting market share.
- Notable pipeline candidates include fenfluramine and cannabidiol derivatives.
Pricing and Reimbursement
- Average Wholesale Price (AWP): Approximately $15 per 100 mg tablet.
- Reimbursement Coverage: Generally covered under insurance plans in North America and Europe, with some restrictions based on indication.
Regulatory and Market Expansion Efforts
- Label Expansion: Eisai is evaluating data for broader pediatric indications.
- Geographic Expansion: Efforts ongoing to secure approvals in emerging markets such as Japan, South Korea, and Brazil.
What is the projection for RUFINAMIDE’s future market?
Market Penetration and Revenue Forecasts (2023-2030)
| Year |
Estimated Revenue |
Key Assumptions |
| 2023 |
$200 million |
Current indications, steady growth |
| 2025 |
$250 million |
Slight expansion into additional seizure types; increased off-label use |
| 2030 |
$350 million |
Broader pediatric approvals, geographic expansion, pipeline competition remains limited |
Market Drivers
- Rising prevalence of Lennox-Gastaut Syndrome and other severe epilepsies.
- Growing acceptance of Rufinamide as monotherapy and adjunct therapy.
- Increasing use in pediatric populations with specific seizure types.
Market Risks
- Competition from newer agents, especially cannabidiol-based therapies.
- Potential regulatory hurdles in countries outside North America and Europe.
- Off-label use limitations and insurance restrictions.
Summary
Rufinamide remains a niche but stable anticonvulsant option primarily for Lennox-Gastaut Syndrome. Current clinical evidence confirms its efficacy and safety, supporting its continued use. Market growth depends on expanding indications, geographic reach, and competition from novel therapies.
Key Takeaways
- Rufinamide primarily targets LGS; clinical trials support efficacy with minimal safety issues.
- The global market is valued at approximately $200 million, with projected growth to $350 million by 2030.
- Expansion into pediatric and broader seizure indications can catalyze revenue growth.
- Competition from cannabidiol derivatives and other newer anticonvulsants poses a challenge.
- Regulatory efforts and pipeline developments are vital to future market expansion.
FAQs
1. What is the primary indication for RUFINAMIDE?
Treatment of Lennox-Gastaut Syndrome in patients aged 4 years and older.
2. How effective is RUFINAMIDE in reducing seizures?
Clinical trials show roughly 45% of patients achieve more than 50% reduction in seizure frequency.
3. Are there ongoing trials for new indications?
No active large-scale trials are confirmed; ongoing observational studies examine off-label uses.
4. What are the main competitors?
Vigabatrin, topiramate, and emerging cannabidiol therapies.
5. What factors could influence RUFINAMIDE’s market growth?
Regulatory approvals for broader indications, pipeline innovations, and geographic expansion.
